RY 142.67 0.2741% TD 73.88 -0.8721% SHOP 90.5 -0.9088% CNR 166.11 0.2414% ENB 47.82 -0.0209% CP 108.03 0.7273% BMO 115.21 0.2088% TRI 229.53 0.0131% CNQ 46.6 0.7568% BN 56.605 0.3991% ATD 76.65 -0.1173% CSU 3771.1299 -0.0005% BNS 63.59 -0.0943% CM 65.25 0.1535% SU 50.11 0.2802% TRP 52.57 0.2288% NGT 56.35 0.1422% WCN 238.17 0.4428% MFC 35.05 0.2001% BCE 44.76 -0.1339%

Cardiol Therapeutics Inc Class A

Healthcare CA CRDL

2.97CAD
-0.31(9.45%)

Last update at 2024-06-17T20:00:00Z

Day Range

2.963.46
LowHigh

52 Week Range

0.611.64
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -30.93065M -31.63824M -20.64093M -13.68402M -15.89373M
Minority interest - - - - -
Net income -11.52226M -31.74424M -20.67539M -13.78387M -15.89373M
Selling general administrative 22.37M 27.87M 9.95M 10.45M 5.87M
Selling and marketing expenses - - - - -
Gross profit - 0.08M - - -
Reconciled depreciation 0.22M 0.22M 0.23M 0.15M 0.09M
Ebit -50.33903M -45.47313M -20.60648M -13.58355M -15.23036M
Ebitda -50.11913M -45.25271M -20.37694M -13.43298M -15.13887M
Depreciation and amortization 0.22M 0.22M 0.23M 0.15M 0.09M
Non operating income net other - - - - -
Operating income -50.33903M -45.47313M -20.60648M -13.58355M -7.49374M
Other operating expenses 41.34M 38.74M 20.69M 14.13M 7.49M
Interest expense 19.41M 0.11M 0.00000M 0.00062M 0.66M
Tax provision - - 0.00000M - -
Interest income 1.24M 6.91M 0.04M 0.15M 7.74M
Net interest income 1.24M 0.11M 0.08M 0.24M -0.56007M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -19.40839M 0.11M 0.03M 0.10M -
Total revenue 0.00000M 0.08M 0.00000M 0.00000M 0.00000M
Total operating expenses 41.34M 38.74M 20.69M 14.13M 7.49M
Cost of revenue - - - - -
Total other income expense net 19.41M 13.83M -0.03445M -0.10047M -8.40000M
Discontinued operations - - - - -
Net income from continuing ops -30.93065M -31.63824M -20.64093M -13.68402M -15.89373M
Net income applicable to common shares -30.93065M -31.63824M -20.64093M -13.68402M -15.89373M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 62.03M 87.88M 15.89M 15.50M 24.68M
Intangible assets 0.29M 0.38M 0.46M 0.55M 0.63M
Earning assets - - - - -
Other current assets - 2.83M 0.69M 5.37M 0.49M
Total liab 9.83M 11.64M 2.62M 0.83M 2.41M
Total stockholder equity 52.20M 76.24M 13.27M 14.67M 22.27M
Deferred long term liab - - - - -
Other current liab 9.75M 11.52M 2.47M 0.64M 0.00990M
Common stock 147.55M 142.92M 51.92M 39.41M 36.72M
Capital stock 147.55M 142.92M 51.92M 39.41M 36.72M
Retained earnings -114.44851M -83.51786M -51.87962M -31.23868M -17.55466M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 59.47M 83.90M 14.03M 6.96M 16.73M
Cash and equivalents 59.47M 83.90M 14.03M 6.96M 16.73M
Total current liabilities 9.80M 11.57M 2.52M 0.69M 2.14M
Current deferred revenue - - - - -
Net debt -59.39700M -83.78149M -13.86862M -6.76545M -16.46228M
Short term debt 0.05M 0.04M 0.05M 0.05M 0.00000M
Short long term debt - - - - -
Short long term debt total 0.07M 0.12M 0.16M 0.19M 0.27M
Other stockholder equity 19.10M 16.84M 13.23M 6.50M 3.12M
Property plant equipment 0.30M 0.36M 0.48M 0.58M 0.03M
Total current assets 61.44M 87.14M 14.95M 14.37M 24.03M
Long term investments - - - - -
Net tangible assets 51.91M 75.86M 12.81M 14.12M 21.64M
Short term investments - - - - -
Net receivables 0.48M 0.41M 0.22M 0.93M 0.46M
Long term debt - - - 0.00000M 0.27M
Inventory - 0.34M 0.02M 1.12M 6.35M
Accounts payable 9.33M 4.14M 1.77M 0.56M 2.14M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -0.22141M -0.07631M -0.01018M
Additional paid in capital - - - - -
Common stock total equity - - 51.92M 39.41M 36.72M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 0.66M
Deferred long term asset charges - - - - -
Non current assets total 0.59M 0.74M 0.94M 1.13M 0.66M
Capital lease obligations 0.07M 0.12M 0.16M 0.19M -
Long term debt total 0.02M 0.07M 0.10M 0.14M 0.27M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.07471M -0.01292M -0.04060M -0.42430M -0.01379M
Change to liabilities 4.47M 2.39M 1.83M -1.50132M 1.96M
Total cashflows from investing activities -0.07471M -0.01292M -0.04060M -0.42430M -0.01379M
Net borrowings -0.05393M -0.05192M -0.05047M -0.02019M 12.07M
Total cash from financing activities -0.05393M 93.44M 16.30M 2.03M 25.28M
Change to operating activities 1.42M -2.27459M -0.06414M 0.23M -0.49023M
Net income -30.93065M -31.63824M -20.64093M -13.68402M -15.89373M
Change in cash -24.42920M 69.87M 7.07M -9.77530M 14.37M
Begin period cash flow 83.90M 14.03M 6.96M 16.73M 2.36M
End period cash flow 59.47M 83.90M 14.03M 6.96M 16.73M
Total cash from operating activities -27.22034M -23.55078M -9.18543M -11.38008M -10.89400M
Issuance of capital stock 0.00000M 84.08M 17.25M 1.67M 14.23M
Depreciation 0.22M 0.22M 0.23M 0.15M 0.09M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 0.00000M 0.02M 1.10M 0.14M -6.34553M
Change to account receivables -0.14418M -0.05995M 0.71M -0.46709M -0.33106M
Sale purchase of stock 0.00000M 98.73M 17.43M 2.05M 14.23M
Other cashflows from financing activities -0.07471M 9.41M -0.90451M 0.38M 11.05M
Change to netincome -2.25762M 7.79M 2.91M 3.77M 9.66M
Capital expenditures 0.07M 0.01M 0.04M 0.42M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 5.75M 0.08M 8.32M -1.62066M -5.20213M
Stock based compensation 5.01M 8.50M 2.77M 3.27M 1.65M
Other non cash items -7.27081M -0.70731M 0.14M 0.51M 8.46M
Free cash flow -27.29505M -23.56369M -9.22603M -11.80438M -10.90780M

Fundamentals

  • Previous Close 3.28
  • Market Cap93.76M
  • Volume278768
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-30.69026M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.08M
  • Diluted EPS TTM-0.43

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CRDL
Cardiol Therapeutics Inc Class A
-0.31 9.45% 2.97 - - 1273.79 2.69 230.52 -1.7446
BHC
Bausch Health Companies Inc
0.15 1.73% 8.82 - 2.10 0.47 18.74 3.89 18.18
TLRY
Tilray Inc
0.005 0.21% 2.35 - 1000.00 2.91 0.45 3.43 -1.9457
CRON
Cronos Group Inc
0.01 0.31% 3.20 - - 11.24 0.67 0.07 1.02
TSND
TerrAscend Corp.
-0.01 0.52% 1.90 - - - -

Reports Covered

Stock Research & News

Profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics Inc Class A

2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5

Key Executives

Name Title Year Born
Mr. David G. Elsley M.B.A., MBA Pres, CEO & Director NA
Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, M.B.A., MBA CFO, Corp. Sec. & Director NA
Mr. Bernard Lim B.Sc. Chief Operating Officer NA
Dr. Andrew Warwick Hamer M.D. Chief Medical Officer & Head of R&D 1962
Trevor Burns Investor Relations NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).